An interventional study of Targeted Blood Pressure Management and Liberal Blood Pressure Management in Coronary Artery Disease and Postoperative Complications, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to learn whether two approaches to anesthesia and blood pressure management can improve care for adults having off-pump coronary artery bypass grafting (OPCAB). OPCAB is a type of heart bypass surgery performed without routinely using a heart-lung machine.
The main questions this study aims to answer are:
The researchers expect that targeted blood pressure management may lower the chance of major postoperative complications. They also expect that remimazolam may provide more stable blood pressure and heart rate than propofol.
Researchers plan to enroll 416 adults having elective OPCAB surgery. Participants will be randomly assigned to one of four groups. Each group will receive one of two blood pressure strategies and one of two medicines for maintaining general anesthesia.
Participants will:
The study will also explore whether the effect of the blood pressure strategy differs depending on which anesthetic medicine is used.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 416 is above the median of 124 across 3,006 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Targeted Blood Pressure Management · Drug: Remimazolam
Other: Targeted Blood Pressure Management · Drug: Propofol
Other: Liberal Blood Pressure Management · Drug: Remimazolam
Other: Liberal Blood Pressure Management · Drug: Propofol
Mean arterial pressure (MAP) will be maintained at 65 mm Hg or higher from induction of anesthesia until completion of surgery. A confirmed MAP below 65 mm Hg will prompt verification of the arterial pressure measurement and treatment directed at the presumed clinical cause. Treatment may include fluids, blood products, vasopressors, inotropes, heart-rate or rhythm management, cardiac repositioning, temporary pacing, or mechanical circulatory support when clinically indicated.
No trial-mandated mean arterial pressure target or study-defined treatment threshold will be imposed. Blood pressure will be managed at the discretion of the attending anesthesiologist according to usual clinical practice, the participant's clinical condition, and surgical conditions. Rescue treatment will be unrestricted when required for participant safety.
Remimazolam will be administered by continuous intravenous infusion for maintenance of general anesthesia beginning immediately after internal jugular vein catheterization. The initial infusion rate will be 1.0 mg/kg/hour and may be titrated within 0.5-1.5 mg/kg/hour according to clinical requirements. The infusion will be discontinued at completion of skin closure.
Propofol will be administered by continuous intravenous infusion for maintenance of general anesthesia beginning immediately after internal jugular vein catheterization. The initial infusion rate will be 1.0 mg/kg/hour and may be titrated within 0.5-1.5 mg/kg/hour according to clinical requirements. The infusion will be discontinued at completion of skin closure.
Incidence of the 30-Day Composite of Postoperative Complications or All-Cause Mortality
Time frame: From postoperative day 1 through postoperative day 30
Incidence of Postoperative Delirium
Time frame: From postoperative day 1 through postoperative day 7
Incidence of Cognitive Decline
Time frame: At postoperative day 7 and postoperative day 30
Incidence of Stroke
Time frame: From postoperative day 1 through postoperative day 30
Incidence of Cardiac Complications
Time frame: From postoperative day 1 through postoperative day 30
Incidence of Respiratory Failure
Time frame: From postoperative day 1 through postoperative day 30
Incidence of Severe Acute Kidney Injury
Time frame: From postoperative day 1 through postoperative day 7
Incidence of Infectious Complications
Time frame: From postoperative day 1 through postoperative day 30
All-Cause Mortality
Time frame: Within 30 days after surgery
Incidence of Intraoperative Hypotension
Time frame: From the start of maintenance anesthesia until completion of surgery
Time-Weighted Average Below 0.80 × T0 Mean Arterial Pressure
Time frame: From the start of maintenance anesthesia until completion of surgery
Incidence of Intraoperative Hypertension
Time frame: From the start of maintenance anesthesia until completion of surgery
Incidence of Intraoperative Bradycardia
Time frame: From the start of maintenance anesthesia until completion of surgery
Incidence of Intraoperative Tachycardia
Time frame: From the start of maintenance anesthesia until completion of surgery
Time-Weighted Mean of the MAP/HR Ratio
Time frame: From the start of maintenance anesthesia until completion of surgery
Incidence of Major Hemodynamic Rescue Interventions
Time frame: From induction of anesthesia until completion of surgery
Incidence of Acute Kidney Injury of Any Stage
Time frame: Within 7 days after surgery
Incidence of New-Onset Atrial Fibrillation
Time frame: Within 30 days after surgery
Incidence of Postoperative Pulmonary Complications
Time frame: Within 30 days after surgery
Incidence of Unplanned Reoperation or Reintervention
Time frame: Within 30 days after surgery
Incidence of Unplanned Hospital Readmission
Time frame: Within 30 days after surgery
Duration of Mechanical Ventilation
Time frame: At extubation, approximately 12 hours after surgery
Intensive Care Unit Length of Stay
Time frame: At ICU discharge, an average of 3 days
Postoperative Hospital Length of Stay
Time frame: At hospital discharge, an average of 7 days
Incidence of Prespecified Anesthetic-Related Safety Events
Time frame: Through hospital discharge, approximately 7 days after surgery
Change in Plasma Phosphorylated Tau 217 Concentration
Time frame: From the preoperative baseline through postoperative day 3
Change in Plasma Neurofilament Light Chain Concentration
Time frame: From the preoperative baseline through postoperative day 3
Change in Plasma Glial Fibrillary Acidic Protein Concentration
Time frame: From the preoperative baseline through postoperative day 3
Cumulative Incidence of the Long-Term Composite Clinical Outcome
Time frame: At 6 and 12 months after surgery
Telephone Montreal Cognitive Assessment Score
Cognitive function will be assessed using the Telephone Montreal Cognitive Assessment (T-MoCA). Scores range from 0 to 22, with higher scores indicating better cognitive function.
Time frame: At 6 and 12 months after surgery
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 14 months is below that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Remimazolam · Propofol
Chinese Academy of Medical Sciences, Fuwai Hospital →